Association of the polymorphisms 292 C>T and 1304 G>A in the SLC38A4 gene with hyperglycaemia

Authors


Dr. Carlos Galaviz-Hernández, Laboratorio de Biología Molecular, CIIDIR-IPN Unidad Durango, Sigma 119 Fracc 20 de Noviembre II, Durango, Dgo, Mexico c.p. 34220.

E-mail: carlosgalavizhernandez55@gmail.com; cgalaviz@ipn.mx

Abstract

Background

The SLC38A4 gene is related to system ‘A’ activity, which seems to be related to impaired gluconeogenesis. The objective of this study was to determine whether the 292 C>T and 1304 G>A polymorphisms of SLC38A4 gene are associated with hyperglycaemia in humans.

Methods

A total of 227 individuals were enrolled in a case–control study, in which hyperglycaemia was defined by plasma glucose levels ≥95 mg/dL. Genotyping was carried out by using real-time polymerase chain reaction.

Results

The frequency of mutant alleles of SLC38A4 gene for single-nucleotide polymorphism (SNP) 1304 G>A was 23.6% and 30.2% for SNP 292 C>T. The frequency of allele T for the SNP 292 C>T in the case and control groups did not show significant differences, whereas the frequency of allele A for the SNP 1304 G>A was significantly higher in the case group than in the control group (p = 0.04). In the logistic regression analysis, the SNP 1304 G>A [odds ratio (OR) 1.78; 95%CI 1.04–3.05, p = 0.03] but not SNP 292 C>T (OR 1.41; 95%CI 0.80–2.47, p = 0.23) showed a significant association with hyperglycaemia. After adjusting by body mass index, waist circumference and triglycerides, the SNP 1304 G>A remained significantly associated with hyperglycaemia (OR 2.13; 95%CI 1.18–3.83, p = 0.03). Pair wise linkage disequilibrium showed correlation (D′ > 0.82) between 292 C>T and 1304 G>A SNPs. Haplotype association with hyperglycaemia also showed significant association between both homozygous mutant alleles (A/T) and hyperglycaemia (OR 1.68; 95%CI 1.01–2.79, p = 0.048).

Conclusions

Our results suggest that mutant allele A for SNP 1304 G>A of SLC38A4 gene is associated with hyperglycaemia. Copyright © 2012 John Wiley & Sons, Ltd.

Ancillary